Abarelix
DB00106
Approved Indication
For palliative treatment of advanced prostate cancer.
1
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.
Details
DrugBank ID
DB00106 ↗
Approval Date
—
Molecular Weight
1416.09 g/mol
Drug Class
Other
ATC Codes
L02BX01
Synonyms
—
PubChem
CID: 16131215 ↗
ChEMBL
CHEMBL1252 ↗
SMILES
CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
ADMET Profile
Computing properties…